Brief: Incannex Engages Catalent For Development And Cgmp Manufacture Of Psilocybin Drug Product For Clinical Trials And Potential Commercial Use
03/03/2023 12:39
March 3 (Reuters) - Incannex Healthcare Ltd IHL.AX :
* INCANNEX ENGAGES CATALENT FOR DEVELOPMENT AND CGMP
MANUFACTURE
OF PSILOCYBIN DRUG PRODUCT FOR CLINICAL TRIALS AND POTENTIAL
COMMERCIAL USE
Source text for Eikon: ID:nGNX74sQWf
Further company coverage: IHL.AX
Recent news on Incannex Healthcare
See all newsBrief: Incannex Healthcare Says Computershare To Be Appointed As US Transfer Agent
Brief: Incannex Healthcare Says Federal Court Of Australia Approved Proposed Schemes Of Arrangement Between Incannex And Its Shareholders
Australia's Incannex up as shareholders in favour of US redomicile
Brief: Incannex Healthcare Will Prepare FDA Ind Application PSI-Gad
Brief: Review Of Ind Application For Ihl-42X By Us FDA Has Been Completed Clinical Trial For Patients With Obstructive Sleep Apnoea May Proceed